Benzamides and related inhibitors of factor Xa
Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula
or a pharmaceutically acceptable salt thereof and a therapeutic agent.
2. The composition of claim 1 , wherein the salt is the maleate salt.
3. The composition of claim 1 , wherein the therapeutic agent is selected from the group consisting of an anticoagulant agent, a thrombolytic agent, and an antithrombotic.
4. The composition of claim 1 , wherein the therapeutic agent is selected from the group consisting of an urokinase, prourokinase, streptokinase, heparin, aspirin, and warfarin.
5. The composition of claim 1 , wherein the therapeutic agent is aspirin.
6. A method for preventing or treating a condition in a mammal in need thereof characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound of the formula
or a pharmaceutically acceptable salt thereof and aspirin.
7. The method of claim 6 , wherein the condition is selected from the group consisting of acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus, occurring post-thrombolytic therapy or post-coronary angioplasty, cerebrovascular syndrome, embolic stroke, thrombotic stroke or transient ischemic attacks, venous thrombosis, pulmonary embolus, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic, disease associated with heparin induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation, and thrombotic complications associated with the fitting of prosthetic devices.
8. The method of claim 6 , wherein the salt is administered in a pharmaceutical compositions comprising the salt and a pharmaceutically acceptable carrier.
9. The method of claim 8 , wherein the salt is the maleate salt.